Centers | ||
|
|
|
Saint Louis University Institute for Drug and Biotherapeutic Innovation (IDBI) | Therapeutic Accelerator Program (TAP) | UCSC Chemical Screening Center |
The IDBI is a decentralized, collaborative institute whose mission is to promote the translation of research projects at Saint Louis University through drug discovery and pre-clinical development. The IDBI achieves this through four main... |
Test |
We are a shared research facility dedicated to improving human health by finding therapeutic agents against a wide variety of diseases, dedicated to advancing scientific knowledge and technologies, and dedicated to education of the next generation of... |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Sanofi to Collaborate with UCSF to Develop New Drugs to Treat DiabetesUniversity of California, San Francisco (UCSF) has entered into a broad collaboration agreement with Sanofi to develop new therapies to treat Diabetes (Type 1 & 2). Scientists with deep biology expertise at Sanofi will be partnering with... View all Argenta and ANTABIO Announce Drug Discovery CollaborationArgenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to proof of concept, announced today that it has achieved a milestone with its collaboration partner Antabio in an anti-bacterial drug... View all |
No EVENTS for listing |
No Job Posts |
